Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
✉ Email this page to a colleague
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-03-15 |
| Court | District Court, D. New Jersey | Date Terminated | 2023-12-29 |
| Cause | 15:1126 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,166,242; 10,166,243; 10,195,214; 10,500,216; 8,921,348; 9,829,495; 9,943,526 | ||
| Attorneys | LAUREN RUTH MALAKOFF | ||
| Firms | Quinn Emanuel Urquhart & Sullivan, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-07-06 | 15 | of United States Patent Nos. 8,921,348 (“’348 patent”), 9,829,495 (“’495 patent”), and 9,943,526 … States Patent (10) Patent No.: US 8,921,348 B2 … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 44. … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 52. … US 8,921,348 B2 1 | External link to document | |
| 2021-05-26 | 202 | Summary Judgment of Infringement of U.S. Patent No. 10,195,214 (Attachments: # 1 Statement in Response … 15 March 2018 1:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
